Research Article

You have full text access to this OnlineOpen article

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

  1. George Nuki1,*,
  2. Barry Bresnihan2,
  3. Moraye B. Bear3,
  4. Dorothy McCabe3,†

Article first published online: 8 NOV 2002

DOI: 10.1002/art.10578

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 46, Issue 11, pages 2838–2846, November 2002

Additional Information

How to Cite

Nuki, G., Bresnihan, B., Bear, M. B. and McCabe, D. (2002), Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 46: 2838–2846. doi: 10.1002/art.10578

Author Information

  1. 1

    University of Edinburgh, Edinburgh, Scotland, UK

  2. 2

    St. Vincent's University Hospital, Dublin, Ireland

  3. 3

    Amgen, Inc., Thousand Oaks, California

  1. †

    IDEC Pharmaceuticals Corp., San Diego, California

*Rheumatic Diseases Unit, Paderewski Building, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, Scotland, UK

Publication History

  1. Issue published online: 8 NOV 2002
  2. Article first published online: 8 NOV 2002
  3. Manuscript Accepted: 3 JUL 2002
  4. Manuscript Received: 27 DEC 2001

Funded by

  • Amgen, Inc.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (93K)

REFERENCES

  • 1
    Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151–60.
    Direct Link:
  • 2
    Dinarello CA. The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000; 343: 732–4.
  • 3
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93.
  • 4
    Brennan FM, Maini RN, Feldmann M. TNF alpha: a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31: 293–8.
  • 5
    Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095–147.
  • 6
    Lipsky PE, van der Heijde DMFM, St Clair WE, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602.
  • 7
    Van den Berg WB. Lessons for joint destruction from animal models. Curr Opin Rheumatol 1997; 9: 221–8.
  • 8
    Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305–15.
    Direct Link:
  • 9
    Seckinger P, Dayer JM. Natural inhibitors of TNF. In: AggarwalBB, VilcekJ, editors. Tumor necrosis factor: structure, function, and mechanism of action. New York: Marcel Dekker; 1992. p. 217–38.
  • 10
    Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334–42.
  • 11
    Moreland LW, Heck LW Jr, Koopman WJ. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997; 40: 397–409.
    Direct Link:
  • 12
    Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–7.
  • 13
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681–90.
    Direct Link:
  • 14
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10.
  • 15
    Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: the IL-1Ra Arthritis Study Group. Arthritis Rheum 1996; 39: 1092–101.
    Direct Link:
  • 16
    Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196–204.
    Direct Link:
  • 17
    Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998; 16: 457–99.
  • 18
    Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994; 37: 644–52.
    Direct Link:
  • 19
    Arend WP. Interleukin 1 receptor antagonist: a new member of the interleukin 1 family. J Clin Invest 1991; 88: 1445–51.
  • 20
    Lebsack ME, Paul CC, Bloedow DC, Burch FX, Sack MA, Chase W, et al. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34 Suppl 9: S45.
  • 21
    Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42: 498–506.
    Direct Link:
  • 22
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35.
    Direct Link:
  • 23
    Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of the Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33: 477–84.
    Direct Link:
  • 24
    Jiang Y, Genant H, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001–9.
    Direct Link:
  • 25
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 26
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45.
    Direct Link:
  • 27
    Genant KH, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998; 41: 1583–90.
    Direct Link:
  • 28
    Larsen A, Dale K, Eck M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977; 8: 481–91.
  • 29
    Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 557–60.
  • 30
    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614–24.
    Direct Link:
View Full Article (HTML) Get PDF (93K)